Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Niagen Bioscience (NAGE) to $11 from $12 and keeps a Buy rating on the shares. The company reported moderate revenue outperformance with earnings in-line, the analyst tells investors in a research note.